Ullah, 60 patient remdesivir late treatment study: 100% higher mortality [p=0.33] and 250% higher ventilation [p=0.15] https://c19p.org/ullah
copied to clipboard
Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore
et al., International Journal of Sciences, doi:10.18483/ijSci.2417
Small late stage (hospitalized, <12 days symptoms) remdesivir study showing non-statistically significant higher mortality with treatment.No adjustments were made for differences in the groups. Remdesivir mean age was 49 vs. control 57. Baseline oxygen requirement was 13.4 liters treatment vs. 10.8 control. Potential confounding by indication.[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
|
risk of death, 100% higher, RR 2.00, p = 0.33, treatment 8 of 30 (26.7%), control 4 of 30 (13.3%).
|
|
risk of mechanical ventilation, 250.0% higher, RR 3.50, p = 0.15, treatment 7 of 30 (23.3%), control 2 of 30 (6.7%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Ullah et al., 11/29/2020, retrospective, Pakistan, South Asia, peer-reviewed, 8 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.